Who is sponsoring NCT00100269?

NCT00100269 is sponsored by Repromed.

What condition does NCT00100269 study?

NCT00100269 studies Infertility, Male, Oxidative Stress.

What drugs are being tested in NCT00100269?

Interventions: Menevit anti-oxidant.

What is the status of NCT00100269?

NCT00100269 is currently COMPLETED.

Last reviewed 2006-05-01 · How we verify

A Randomized Control Trial of the Menevit Anti-Oxidant Therapy for the Treatment of Male Infertility

NCT00100269 Phase 3 COMPLETED

Oxidative stress related damage to sperm is believed to be a major cause of male infertility. The object of the Menevit study is to investigate the role of a novel anti-oxidant preparation (Menevit) on sperm function, embryo quality and pregnancy rates in an in vitro fertilization (IVF) setting.

Details

Lead sponsor	Repromed
Phase	Phase 3
Status	COMPLETED
Enrolment	60
Start date	2004-12
Completion	2006-03

Conditions

Infertility, Male
Oxidative Stress

Interventions

Menevit anti-oxidant

Primary outcomes

Embryo quality (morphology score, progression to blastocyst rates, number of embryos available for freezing/transfer per cycle)
Embryo quality is a good measure of pregnancy potential and is also an indicator of sperm DNA integrity, making it the ideal primary endpoint.

Countries

Australia